Research: FIORELLA and LORNA, 

Listed in Issue 287


FIORELLA and LORNA,  1 Universidad del Desarrollo-Clínica Alemana, Santiago, Chile; 2 Department of Neurology, Clínica Alemana, Santiago, Av Vitacura 5951, Vitacura, Santiago, Chile.  tested immunosuppressant agents as potential treatment for coronavirus 2019 (COVID-19) in patients with multiple sclerosis (MS).


The severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) is a novel disease that has spread abruptly over the world, allowing the development of countermeasures an urgent global priority. It has been speculated that elder people and patient with comorbidities may be at risk of developing complications. On the other hand, it has been seen that immunosuppressed patients could develop a mild presentation of the disease. Based on this hypothesis, several immunosuppressant agents are currently being tested as potential treatment for coronavirus 2019 (COVID-19).


The authors report a patient treated with alemtuzumab (Humanized monoclonal antibody against the lymphocyte and monocyte surface antigen CD52, which depletes B and T cells) (Thompson et al., 2018) for recurrent remittent multiple sclerosis (RRMS) who developed mild COVID-19.


Despite complete B and T cell depletion, patient symptoms abated few days with no need for hospitalization due to COVID-19 and no clinical evidence of disease activation regarding her MS.


This report shows that MS patients with mild depletion of B and T cells can mount an antiviral response against COVID-19 and produce IgG. Copyright © 2020 Elsevier B.V. All rights reserved.


Celsi Fiorella  1 , Galleguillos Lorna  2  COVID-19 in a multiple sclerosis (MS) patient treated with alemtuzumab: Insight to the immune response after COVID . Mult Scler Relat Disord.;46:102447. Nov 2020  doi: 10.1016/j.msard.2020.102447. Epub 2020 Aug 10.

ICAN 2024 Skyscraper

Scientific and Medical Network 2

Cycle Around the World for Charity 2023

Climb Mount Kilimanjaro Charity 2023

top of the page